Structure−Activity Relationship of Quinoline Derivatives as Potent and Selective α2C-Adrenoceptor Antagonists
摘要:
Starting from two acridine compounds identified in a high-throughput screening campaign (1 and 2, Table 1), a series of 4-aminoquinolines was synthesized and tested for their properties on the human alpha(2)-adrenoceptor subtypes (alpha(2A), alpha(2B), and alpha(2C.)). A number of compounds with good antagonist potencies against the alpha(2C)-adrenoceptor and excellent subtype selectivities over the other two subtypes were discovered. For example, (R)-{4-[4-(3,4-dimethylpiperazin-1-yl) phenylamino] quinolin- 3- yl} methanol 6j had an antagonist potency of 8.5 nM against, and a subtype selectivity of more than 200-fold for, the alpha(2C)-adrenoceptor. Investigation of the structure-activity relationship identified a number of structural features, the most critical of which was an absolute need for a substituent in the 3-position of the quinoline ring. The 3-position on the piperazine ring was also found to play an appreciable role, as substitutions in that position exerted a significant and stereospecific beneficial effect on the alpha(2C)-adrenoceptor affinity and potency. Replacing the piperazine ring proved difficult, with 1,4-diazepanes representing the only viable alternative.
4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
申请人:AGOURON PHARMACEUTICALS, INC.
公开号:EP1215208B1
公开(公告)日:2006-07-12
INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER
申请人:Treu Matthias
公开号:US20100184747A1
公开(公告)日:2010-07-22
The present invention encompasses compounds of general formula (1) wherein R
1
to R
4
are defined as in claim
1
, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.
[EN] INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER<br/>[FR] DÉRIVÉS D'INDOLINONE ET LEUR UTILISATION DANS LE TRAITEMENT D'ÉTATS PATHOLOGIQUES TELS QUE LE CANCER
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2008152013A1
公开(公告)日:2008-12-18
[EN] The present invention encompasses compounds of general formula (1) wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties. [FR] La présente invention concerne des composés de formule générale (1), les R1 à R4 étant définis tels que dans la revendication 1, qui sont appropriés pour traiter des maladies caractérisées par une prolifération cellulaire excessive ou anormale, et leur utilisation pour préparer une composition pharmaceutique ayant les propriétés mentionnées ci-dessus.